An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis / Necchi, A; Giannatempo, P; Raggi, D; Mariani, L; Colecchia, M; Fare, E; Monopoli, F; Calareso, G; Ali, Sm; Ross, Js; Chung, Jh; Salvioni, R. - In: EUROPEAN UROLOGY. - ISSN 0302-2838. - 75:1(2019), pp. 201-203. [10.1016/j.eururo.2018.09.010]
An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis
Necchi A;Colecchia M;
2019-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
